A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)
Recruiting · Phase 3 · NCT06911502
Conditions: Follicular Lymphoma
At a glance
- Research payments reported, 2025
- $319,963
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 400
About the trial
- Sponsor
- Celgene
- Tested
- Golcadomide (drug), Rituximab (drug), Lenalidomide (drug), Cyclophosphamide (drug), Doxorubicin (drug), Vincristine (drug), Prednisone/Prednisolone (drug), Bendamustine (drug)
- Dates
- Started 2025-07-28; completion 2030-07-31
- Results posted
- Not yet
The study is designed as a multicenter, randomized, open label Phase 3 study to compare the efficacy and safety of golcadomide in combination with rituximab vs investigator's choice in participants with relapsed/refractory follicular lymphoma who have received at least one line of prior systemic therapy.
From ClinicalTrials.gov, last updated 2026-05-20. Full record, eligibility and contacts (opens in a new tab)
Industry funding
E.r. Squibb & Sons, L.l.c. reported $319,963 in research payments for this study in 2025 (7 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Rhode Island Hospital $318,284
- $1,679
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.